Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.17 +0.00 (+0.59%)
As of 08:29 AM Eastern
Compare

OBD vs. IMM, SBTX, AREC, OKYO, and AOR

Should you buy Oxford BioDynamics stock or one of its competitors? MarketBeat compares Oxford BioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford BioDynamics include ImmuPharma (IMM), SkinBioTherapeutics (SBTX), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to ImmuPharma?

Oxford BioDynamics (LON:OBD) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

ImmuPharma has a net margin of 3,519.56% compared to Oxford BioDynamics' net margin of -1,018.54%. Oxford BioDynamics' return on equity of -316.67% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
ImmuPharma 3,519.56%-1,397.44%-43.00%

25.4% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 8.1% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 2.975, indicating that its stock price is 198% more volatile than the broader market.

ImmuPharma has lower revenue, but higher earnings than Oxford BioDynamics. ImmuPharma is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M6.66-£103.52M-£0.80N/A
ImmuPharmaN/AN/A-£2.51M-£0.89N/A

In the previous week, ImmuPharma had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for Oxford BioDynamics. ImmuPharma's average media sentiment score of 0.84 beat Oxford BioDynamics' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Oxford BioDynamics Neutral
ImmuPharma Positive

Summary

Oxford BioDynamics and ImmuPharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to SkinBioTherapeutics?

SkinBioTherapeutics (LON:SBTX) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

SkinBioTherapeutics has higher revenue and earnings than Oxford BioDynamics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£4.64M5.45-£3.71M-£0.31N/A
Oxford BioDynamics£1.10M6.66-£103.52M-£0.80N/A

SkinBioTherapeutics has a net margin of -15.01% compared to Oxford BioDynamics' net margin of -1,018.54%. SkinBioTherapeutics' return on equity of -10.01% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-15.01% -10.01% -61.18%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

4.0% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SkinBioTherapeutics has a beta of 0.466, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, SkinBioTherapeutics had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for Oxford BioDynamics. SkinBioTherapeutics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Oxford BioDynamics Neutral

Summary

SkinBioTherapeutics beats Oxford BioDynamics on 7 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Arecor Therapeutics?

Arecor Therapeutics (LON:AREC) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Arecor Therapeutics has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M14.54-£10.68M£2.0033.00
Oxford BioDynamics£1.10M6.66-£103.52M-£0.80N/A

Arecor Therapeutics has a net margin of 38.74% compared to Oxford BioDynamics' net margin of -1,018.54%. Arecor Therapeutics' return on equity of 14.26% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

6.0% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arecor Therapeutics had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Arecor Therapeutics and 0 mentions for Oxford BioDynamics. Arecor Therapeutics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Oxford BioDynamics Neutral

Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

Arecor Therapeutics beats Oxford BioDynamics on 9 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to OKYO Pharma?

OKYO Pharma (LON:OKYO) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
OKYO Pharma Neutral
Oxford BioDynamics Neutral

OKYO Pharma has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-£6.70M-£0.01N/A
Oxford BioDynamics£1.10M6.66-£103.52M-£0.80N/A

OKYO Pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. Oxford BioDynamics' return on equity of -316.67% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A -397.13% -154.72%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

OKYO Pharma has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

25.4% of Oxford BioDynamics shares are held by institutional investors. 31.9% of OKYO Pharma shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Oxford BioDynamics beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to AorTech International?

Oxford BioDynamics (LON:OBD) and AorTech International (LON:AOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

25.4% of Oxford BioDynamics shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AorTech International has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. AorTech International's return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
AorTech International N/A N/A N/A

AorTech International has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M6.66-£103.52M-£0.80N/A
AorTech International£539K0.00N/A-£3.70N/A

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled AorTech International'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
AorTech International Neutral

Summary

Oxford BioDynamics beats AorTech International on 5 of the 8 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£7.30M£476.31M£6.32B£2.79B
Dividend YieldN/A3.87%2.69%6.13%
P/E Ratio-0.213.1621.04364.83
Price / Sales6.666,697.20559.5287,614.39
Price / Cash3.9813.1342.3127.85
Price / Book0.2187.369.937.83
Net Income-£103.52M-£96.07M£3.56B£5.88B
7 Day Performance-5.03%0.48%-0.44%6.72%
1 Month Performance-22.73%1.23%4.59%9.93%
1 Year Performance-62.88%72.00%27.59%75.98%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.17
+0.6%		N/A-62.4%£7.30M£1.10MN/A45
IMM
ImmuPharma
N/AGBX 4.30
flat		N/A+68.1%£26.83MN/AN/A13
SBTX
SkinBioTherapeutics
N/AGBX 9.75
+0.5%		N/AN/A£25.27M£4.64MN/A11
AREC
Arecor Therapeutics
N/AGBX 65.91
-0.1%		N/A+55.3%£24.89M£1.71M32.9610
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/AN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel